Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.49

€0.49

1.440%
0.007
1.440%
€0.70
 
27.03.24 / Frankfurt WKN: A14M04 / Name: Poxel / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Poxel S.A. Stock

Poxel S.A. gained 1.440% today.
The community is currently still undecided about Poxel S.A. with 1 Buy predictions and 0 Sell predictions.
So far the community has only identified positive things for Poxel S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Poxel S.A. in the next few years

Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Poxel S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Poxel S.A. 1.440% -4.537% 19.879% -28.540% -8.426% -92.652% -94.189%
Valneva SE 1.430% 6.985% 13.651% -21.919% -23.883% -65.029% 5.370%
Nanobiotix -0.540% -2.116% -7.191% 75.633% -13.551% -57.955% -48.516%
Transgene S.A. -0.550% -3.220% 6.287% -41.514% -19.254% -57.981% -60.939%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-07

Looking at the financial statements of Poxel, a biotechnology and medical research company, it is evident that the firm has experienced a challenging financial performance in recent years. A quick assessment of the company's financials reveals a decrease in total assets and an increase in total liabilities. The company's net income has also been in the negative territory. Nonetheless, Poxel operates in a high-risk, high-reward industry which could justify the massive investments in research and development and ultimately impact its financials.

Investments in Research and Development: Poxel consistently invests a significant amount in research and development, which is crucial for a biotechnology company. This commitment to R&D could potentially lead to valuable discoveries and breakthrough innovations in the future, translating into substantial revenue and profits for the company.

Cash Reserves: The company maintains a considerable cash balance, which is beneficial for a research-based company. This cash can be used to fund ongoing operations, acquisitions, and investments in cutting-edge research, offering a buffer against potential financial challenges.

Comments

Prediction Sell
Perf. (%) 56.92%
Target price
Change
Ends at 29.01.20

Sell beendet
Show more

Sell Poxel S.A.
Show more

Prediction Buy
Perf. (%) -21.69%
Target price 9.000
Change
Ends at 04.11.21

Buy with target price 9.0
Show more

News

Poxel to Report Its 2023 Annual Results by the End of April 2024: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel to Report Its 2023 Annual Results by the End of April 2024


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Poxel Announces its Financial Calendar for 2024: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces its Financial Calendar for 2024


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic